The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Esnault, S.
Right arrow Articles by Malter, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Esnault, S.
Right arrow Articles by Malter, J. S.
The Journal of Immunology, 1999, 163: 5228-5234.
Copyright © 1999 by The American Association of Immunologists

Primary Peripheral Blood Eosinophils Rapidly Degrade Transfected Granulocyte-Macrophage Colony-Stimulating Factor mRNA1

Stéphane Esnault and James S. Malter2

Department of Pathology and Laboratory Medicine, University of Wisconsin Medical School, Madison, WI 53792


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Despite increasing interest, very little information exists regarding gene regulatory mechanisms employed by eosinophils. This largely stems from the difficulty in transfecting these primary cells. In this study, we demonstrate that peripheral blood eosinophils (PBEos) can be successfully transfected with both GM-CSF cDNA and mRNA and reporter constructs by particle-mediated gene transfer. The transfection efficiency was 1.2% based on green fluorescent protein-positive cells. Promoter studies revealed CMV-driven expression vectors were initially active but rapidly quenched, while viral long terminal repeats had greater activity, indicating that certain viral constructs may be relatively poor to direct the production of transgenic proteins in PBEos. Exogenous GM-CSF mRNA was readily delivered and detected by Northern blot, permitting determination of its t1/2 in the absence of transcriptional poisons. These data show PBEos rapidly degraded GM-CSF mRNA with a t1/2 of 8 min. Mutant GM-CSF mRNAs, lacking the AUUUA motifs, were more stable, but were still rapidly degraded, suggesting the existence of accessory, destabilizing elements. We were able to measure minute amounts of intracellular GM-CSF after the transfection of mutant GM-CSF mRNA, but extracellular cytokine was below the sensitivity of our ELISA. However, the presence of secreted GM-CSF was established by in vitro, survival bioassay. In conclusion, the existence of this new technology should allow detailed studies of eosinophil-specific transcriptional and posttranscriptional regulation.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Eosinophils are critical effector cells in allergic diseases including asthma. Upon allergic challenge, they are recruited from the peripheral blood, and move through the endothelium and pulmonary interstitium into the airways (1, 2, 3). Pulmonary-derived eosinophils are resistant to apoptosis (4), express increased numbers of cell surface cytokine receptors (5), and exhibit enhanced functional and secretory capacity (1, 6). The migration and differentiation of peripheral blood eosinophils (PBEos)3 are driven by cytokine and chemokine gradients (7, 8). In particular, GM-CSF participates in the recruitment, survival, and activation of eosinophils both in vitro and in vivo (9, 10). GM-CSF is expressed by activated immune cells, fibroblasts, and eosinophils themselves, suggesting it functions as both an autocrine and paracrine factor (11, 12, 13).

Despite its importance, the underlying molecular mechanisms that control GM-CSF production by PBEos remain essentially unknown. In resting T lymphocytes, cytokine mRNAs such as GM-CSF are rapidly degraded, preventing mRNA accumulation and translation. Within a few hours of activation with phorbol ester or mitogenic anti-CD3 and anti-CD28 Abs, GM-CSF mRNA was stabilized (14, 15). Under these conditions, transcriptional up-regulation was very modest, accounting for under 10% of the observed accumulation of GM-CSF mRNA. Regulated mRNA decay required the presence of 3'-untranslated region (UTR) adenosine-uridine (AUUUA) repeats (16). Recently, several AUUUA-specific mRNA-binding proteins have been identified that most likely interact with and control the decay of unstable mRNAs (17, 18, 19, 20, 21). On the basis of these data, we have investigated GM-CSF mRNA decay in the eosinophil-like cell line, AML14.3D10 (22). Consistent with the data from T cells, GM-CSF mRNA was extremely unstable in this line, but could be rapidly stabilized by ionophore-mediated cell activation. In addition, multiple mRNA-binding proteins were detected that may participate in GM-CSF mRNA regulation.4

The introduction of genes or mRNA into PBEos is an essential next step to verify that the posttranscriptional control observed in eosinophil-like cell lines occurs in normal cells. A variety of different methods have been used for transient transfection, including calcium phosphate, DEAE dextran, electroporation, cationic liposomes, or viral-mediated gene transfer (23, 24, 25). We and others have shown that plasmid DNA or in vitro transcribed, capped, and adenylated mRNA could be efficiently transfected into cell lines, primary lymphoid cells, or animals by particle-mediated gene transfer (PMGT) (26, 27, 28). Irrespective of methodology, the successful transfection of PBEos has not been reported. In this study, we show that PBEos can be transfected with low but adequate efficiency with GM-CSF expression vectors or coding mRNA as well as reporter constructs. CMV-directed transcription was rapidly quenched in PBEos compared with transformed cells, but long terminal repeats (LTRs) had greater activity. GM-CSF mRNA transfection was as efficient as recently described for an eosinophil-like cell line, AML14.3D10 (22), permitting the determination of GM-CSF mRNA t1/2 in resting and activated cells. Exogenous mRNA was translated, and despite very low levels of extracellular GM-CSF, transfected PBEos showed significantly prolonged in vitro survival.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Reagents and cell cultures

The AML14.3D10 cell line was generously provided by Cassandra Paul (Wright State University, Dayton, OH). The cells were maintained in RPMI 1640 medium, 8% FCS, 2 mM L-glutamine, 1 mM sodium pyruvate, 5 x 10-5 M 2-ME, and 50 µg/ml gentamicin, all from Life Technologies (Grand Island, NY). The K562 cell line was purchased from the American Type Culture Collection (ATCC, Manassas, VA) and was maintained in the same medium as AML14.3D10 cell line.

Subjects and eosinophil separation

Peripheral blood was obtained by venipuncture from patients with allergic rhinitis or asthma. Informed consent was acquired according to a protocol approved by the University of Wisconsin Human Subjects Committee.

Eosinophils were purified using a negative immunomagnetic procedure, as previously described (29). Briefly, heparinized whole blood was centrifuged (700 x g, 20 min) over a Percoll density gradient (density 1.090 g/ml; Pharmacia Biotech, Piscataway, NJ) to separate mononuclear cells from granulocytes. After removal of the mononuclear cell band, RBC were lysed by twice incubating (for 30 s) with sterile, deionized water. The remaining white blood cells were incubated with anti-CD16-coated microbeads (100 ml per 108 cells) for 40 min, and were then passed through steel mesh columns that had been previously washed with 2% newborn calf serum. The cells in the eluent were stained (Diff Quik; Baxter, Miami, FL), and 400 cells were examined microscopically. The cells were used only if >99% of the cells were eosionophils. The few contaminating cells were either neutrophils or mononuclear cells. After isolation, PBEos were maintained in RPMI 1640 medium, 10% FCS, and 50 µg/ml gentamicin, at 37°C in a 5% CO2 environment.

Plasmid constructions

cDNA coding for human GM-CSF was obtained from the ATCC. Using overlap extension PCR, the adenosine-uridine-rich elements (AREs) of wild-type GM-CSF (GM-AUUUA) were selectively replaced with four tandem AUGUA sequences (GM-AUGUA) (27). The full-length mutant GM-AUGUA cDNA was ligated into an expression vector with a CMV promoter and 3' SV40 polyadenylation signal, as previously described (27). Plasmids for in vitro, wild-type, or mutant GM-CSF mRNA synthesis have been described previously (28), and contained complete 5'-UTRs, coding, and 3'-UTRs, except as noted above for GM-AUGUA. In addition, all in vitro transcripts were capped and terminated with a 90-base polyadenylate tail. After production, mRNAs were phenol/chloroform extracted and precipitated at -20°C. The quality and the quantity of synthesized mRNAs were verified by agarose gel electrophoresis and by absorbance at 260 nm.

An LTR-driven plasmid coding for enhanced green fluorescent protein (EGFP) was generously provided by N. S. Kumar and M. Zaboikin (University of Wisconsin, Madison, WI).

cDNA and mRNA transfection

PMGT of expression vectors or in vitro transcribed mRNAs into cultured cells was performed using the Accell Gene-Gun (PowderJect, Madison, WI), as previously described (26, 28, 30). Briefly, mRNAs in aqueous solution were precipitated at -20°C for 1 h with 1 vol of 2-propanol and 0.10 vol of 5 M ammonium acetate onto 1-µm gold beads at a concentration of 5 µg of mRNA/mg of gold beads. A total of 80–95% of the input mRNA was typically loaded onto the beads. Successive transfections of 2 x 106 cells were pooled and washed twice in culture medium to remove any extracellular mRNAs. The transfected PBEos were placed in culture at 1 x 107 cells/ml. cDNAs were loaded onto beads at 1 µg/mg of gold beads with 0.2 M CaCl2 and 10% PEG4000. Transfected K562 and AML14.3D10 cell lines were placed in culture at 1 x 106 cells/ml.

Northern blotting

At indicated times, cells were pelleted and lysed in TRIreagent (Molecular Research Center, Cincinnati, OH), and total RNA was quantitatively isolated and analyzed by Northern blotting with a radioactively labeled, antisense GM-CSF riboprobe, as described previously (19). GM-CSF mRNA signals were normalized to those for GAPDH or actin mRNA to accommodate any differences in the extraction, gel loading, and transfer of total RNA. After stringent washing at 70°C for 5 min with 0.1x SSC, 0.1% SDS, the blots were quantitated by PhosphorImaging (Molecular Dynamics, model 445SI).

Measurement of GM-CSF proteins in conditioned medium and cell lysates

Cells were lysed by incubation for 20 min in 25 mM Tris-HCl (pH 8), 0.1 mM EDTA, 20 mg/ml Pefabloc (Boehringer Mannheim, Indianapolis, IN), and 0.5% Nonidet P-40. Cytoplasmic or media samples were centrifuged at 12,000 x g for 2 min, and supernatants were stored at -80°C until assayed with commercial ELISA kits (Cytoscreen; Biosource, Camarillo, CA) (sensitivity 1 pg/ml), according to the manufacturer’s recommended procedure.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Successful transfection of PBEos by PMGT

To identify gene regulatory mechanisms employed by PBEos for the controlled production of GM-CSF, we sought an easy and reliable transfection method for the introduction of cDNA or mRNA. PMGT has been successfully employed for the introduction of genes into normal cells and tissues that are resistant to other transfection methods (26). Thus, we evaluated transfection efficiency and cell death after PMGT with different sizes of gold beads (0.6–5 µm in diameter) and particle velocity. The latter was varied by adjusting the propulsive gas pressure. Optimal conditions were obtained with 1-µm-diameter beads and 450 PSI, which resulted in <10% cell death (not shown). These were identical to previously optimized conditions for the transfection of primary lymphocytes (28). To assess transfection efficiency, we delivered an LTR-driven, EGFP expression plasmid into PBEos. Five hours after transfection, cells were pelleted and fixed onto cover slips, and positive cells were counted by fluorescence microscopy. In repeat experiments, 10–15 cells per 1000 were unambiguously positive (see Fig. 1Go) for an average transfection efficiency of 1.2%. Despite the very high purity of the initial PBEos population (>99% based on morphological examination after preparation), it remained possible that a contaminating cell population was transfected. However, as shown in Fig. 1Go, many of the fluorescent cells clearly had bilobed nuclei, heavy granularity, and cell diameters characteristic of PBEos.



View larger version (69K):
[in this window]
[in a new window]
  		FIGURE 1. Expression of EGFP in transfected PBEos. Purified eosinophils were transfected with an LTR-driven, EGFP expression plasmid. After 5-h incubation at 37°C, eosinophils were fixed with 4% of paraformaldehyde and examined with a fluorescent microscope (objective x40; Olympus, model A113RFCA). The bright cells in the center have characteristic eosinophil morphology (bilobed nucleus and high granularity).

 
We next investigated whether expression constructs were active in PBEos. Positive results could lead to the successful expression of transgenic proteins by PBEos, which heretofore has been impossible. To put these studies in context, we compared transgene mRNA and protein expression by PBEos with the eosinophil-like AML14.3D10 cell line and widely used human erythroleukemia line, K562. Identical amounts of a CMV-driven, GM-CSF expression vector (pCMV-GM) (28), which also contains a 3' SV40 polyadenylation signal, were loaded onto gold beads (1 µg DNA/1 mg gold beads). In a previous study, PBMC showed peak steady state levels of GM-CSF mRNA at 12 h posttransfection (19). Herein, transfected K562 cells expressed high levels of GM-CSF mRNA for >48 h, which peaked at ~4 h (Fig. 2GoA, K562). Transfected AM14.3D10 accumulated substantially less GM-CSF mRNA than K562 cells. Expression peaked at 1 h after transfection and rapidly decreased over the next 4 h (Fig. 2GoA, AML14.3D10). In both cell lines, GM-CSF mRNA levels and transfected plasmid content (as determined by PCR; data not shown) decreased proportionally. In PBEos, GM-CSF mRNA accumulation was much more abbreviated than even in AML14.3D10 cells, with maximal levels immediately after transfection, which decreased by 50% after 40 min (Fig. 2GoA, PBEos). Despite rapidly decreasing mRNA levels, pCMV-GM could be easily detected by PCR for at least 24 h (data not shown). Thus, compared with the two cell lines, CMV-driven transcription was rapidly suppressed in PBEos despite the continued presence of plasmid. GM-CSF secretion (Fig. 2GoB) generally mirrored intracellular mRNA levels, with the highest levels secreted by K562 cells, much less by AML14.3D10 cells, and undetectable amounts by PBEos.



View larger version (18K):
[in this window]
[in a new window]
  		FIGURE 2. Steady state accumulation of mutant GM-CSF mRNAs in resting PBEos, AML14.3D10, or K562 cell lines. A, PBEos, AML14.3D10, or K562 cell lines were transfected with pCMV-GM or blank gold beads (denoted BK). At the indicated times after transfection, equal numbers of cells were harvested, and RNA was isolated for Northern blotting. Signals were visualized using a PhosphorImager after hybridization with 32P-labeled, antisense GM-CSF riboprobe or GAPDH cDNA probe. B, Transgenic GM-CSF protein in the culture medium was measured at the indicated time points using a human GM-CSF-specific ELISA. Values shown are representative of three experiments for PBEos and two experiments for AML14.3D10 or K562 cell lines.

 
GM-CSF mRNA is very unstable in transfected PBEos

Due to prior data from T lymphocytes, we anticipated GM-CSF gene regulation in PBEos would involve a substantial component of posttranscriptional control, especially at the level of mRNA stability (15). Like most cytokines, GM-CSF mRNA accumulation is antagonized in resting cells by rapid cytoplasmic decay mediated by the 3'-UTR, AREs (16, 28). Thus, PBEos were transfected either with wild-type GM-CSF mRNA or a mutant version containing AUGUA repeats instead of AREs. All mRNAs were capped at the 5' end and terminated with a 90-base polyadenylate tail (28). The decay rate was followed by Northern blotting at various times after transfection. GM-CSF protein was also measured to verify exogenous GM-CSF mRNAs were translated. As shown (Fig. 3Go, A and B), wild-type GM-CSF mRNA was readily detectable by Northern blotting immediately after transfection, but was rapidly degraded with a t1/2 of 8 min. Mutant GM-CSF mRNA was almost 3-fold more stable than wild-type message (t1/2 = 22 min), demonstrating the potent destabilizing effect of the AUUUA motifs (Fig. 3Go, A and B). However, the rapidity of decay of the mutant mRNA suggests the existence of cryptic, destabilizing domains external to the AREs. Importantly, transfection with naked gold beads failed to induce detectable, endogenous GM-CSF mRNA (Fig. 3GoA, BK lanes). In addition, in vitro transcribed GM-CSF mRNAs are slightly smaller than their endogenous counterparts due to their somewhat shorter polyadenylate tail. Thus, on side by side Northern blots, a clear difference between them can be appreciated (not shown). Thus, the hybridization signals in Fig. 3Go reflect only transfected, intracellular mRNA rather than endogenous message. Resting PBMC (28) and the eosinophil-like AML14.3D10 cell line (22) degraded transfected wild-type and mutant GM-CSF mRNAs at rates nearly identical with that seen in PBEos. Therefore, it is likely that similar mechanisms are employed by these different cells to rapidly degrade GM-CSF mRNA.



View larger version (29K):
[in this window]
[in a new window]
  		FIGURE 3. GM-CSF mRNA decays rapidly in transfected PBEos. Resting PBEos were transfected either with capped, polyadenylated wild-type, or mutant GM-CSF mRNAs, or with naked beads alone (BK) via PMGT. Immediately after transfection, cells were washed twice and then placed in culture. A, At the indicated time points, equal numbers of cells were harvested and total RNA was quantitatively isolated and Northern blotted with 32P-labeled antisense riboprobe for GM-CSF or cDNA probe for GAPDH. Signals were visualized using a PhosphorImager. Data presented are representative of three experiments. B, Radioactive signals were quantified using a PhosphorImager. Transfected wild-type or mutant GM-CSF mRNA signals were normalized to GAPDH mRNA and plotted vs time. Each point is the mean ± SD of three experiments. The vertical dashed lines denote the t1/2 of the respective mRNAs.

 
Ionophore stabilizes wild-type but not mutant GM-CSF mRNA

Activation of PBEos with a variety of stimulators including calcium ionophore (ionomycin) triggers GM-CSF mRNA accumulation and protein secretion (12, 31). In mast cells and T lymphocytes, similar agonists have been shown to stabilize GM-CSF, IL-3, IFN-{gamma}, and TNF-{alpha} mRNAs (15, 32, 33). Previously, we observed that GM-CSF mRNA was stabilized in ionomycin-stimulated AML14.3D10 cells (22). Thus, we asked whether ionomycin modulated GM-CSF mRNA stability in PBEos. Cells were treated with ionomycin for 5 h before transfection with wild-type or mutant GM-CSF mRNAs. The stability of transfected mRNAs was then followed by Northern blotting. As shown in Fig. 4Go, A and B, exogenous GM-CSF mRNA was stabilized ~3-fold to a t1/2 of 22 min. The t1/2 of the mutant lacking 3'-UTR AREs was unchanged (t1/2 = 18 min). In all cases, endogenous GM-CSF mRNA was undetectable by Northern blotting due to the small amount of RNA loaded per lane. When we loaded larger amounts of total RNA and increased the PhosphorImager exposure time, endogenous message was detectable by Northern blot after 5-h ionomycin treatment in the absence of transfection (not shown). These data demonstrate that ionomycin stabilizes GM-CSF mRNA and that this effect requires the 3'-UTR AREs.



View larger version (26K):
[in this window]
[in a new window]
  		FIGURE 4. Ionomycin stabilizes transgenic GM-CSF mRNA. Resting or ionomycin-activated eosinophils were transfected with either wild-type (A) or mutant (B) GM-CSF mRNA, or with naked beads alone ("B" lanes). At the indicated time points, equal numbers of cells were harvested and total RNA was quantitatively isolated and Northern blotted with 32P-labeled riboprobe for GM-CSF or cDNA probe for ß-actin. Signals were visualized using a PhosphorImager. Data presented are representative of three experiments. Radioactive signals were quantified using a PhosphorImager. Transfected wild-type (C) or mutant (D) GM-CSF mRNA signals were normalized to ß-actin mRNA and plotted vs time. Each point is the mean ± SD of three experiments. The vertical dashed lines denote the t1/2 of the respective mRNAs.

 
Transfected mRNAs are translated

GM-CSF mRNA most likely requires ongoing translation for normal decay (34). We have previously shown that GM-CSF mRNAs transfected into PBMC by PMGT were >90% polysome associated (28). Indeed, 2 h after transfection with mutant GM-CSF mRNA, supernatants contained 160 pg GM-CSF/ml/106 PBMC or 30 pg GM-CSF/ml/107 AML14.3D10, respectively (22, 28). Due to its rapid decay, PBMC or AML14.3D10 transfected with wild-type GM-CSF mRNA failed to secrete detectable GM-CSF (22, 28). Thus, at 1, 2, or 3 h posttransfection, PBEos supernatants were harvested and analyzed for GM-CSF by ELISA (sensitivity >1 pg/ml). Somewhat unexpectedly, we were unable to measure GM-CSF from PBEos after transfection with either wild-type or mutant GM-CSF mRNA (Table IGo). However, resting PBEos have been reported to accumulate cytokines, including IL-4 and IL-10, in cytoplasmic granules (35). Therefore, 1 h after transfection, PBEos were lysed, and total, cytoplasmic GM-CSF levels were measured by ELISA. Untreated PBEos or those transfected with blank gold beads had undetectable GM-CSF, while those transfected with mutant GM-CSF mRNA contained 7.94 pg GM-CSF/10 µg protein (Table IGo). While these levels of GM-CSF are low, they demonstrate that transfected mRNAs are translationally competent and at least some exogenous mRNA is polysome associated.


View this table:
[in this window]
[in a new window]
  		Table I. GM-CSF production by PBEos transfected with GM-CSF mRNA1

 
It remained possible, however, that the GM-CSF ELISA data were falsely positive due to the high concentration of irrelevant protein in the lysate. Thus, we sought an independent demonstration of GM-CSF production and secretion after mRNA transfection. It is well established that GM-CSF acts as a potent inhibitor of PBEos apoptosis (36). Thus, we examined whether transfected PBEos displayed prolonged in vitro survival. On posttransfection day 4, PBEos were stained with trypan blue and viability was determined. As shown in Fig. 5Go, only 16% of PBEos transfected with naked gold beads were viable after 4 days in culture. The addition of anti-GM-CSF-neutralizing Ab had a minimal and statistically insignificant additional effect. However, PBEos transfected with either wild-type or mutant GM-CSF mRNAs showed significantly increased survival, which was greatest after the transfection of mutant GM-CSF mRNA. In both cases, survival was completely attenuated by anti-GM-CSF Ab (Fig. 5Go), but unaffected by irrelevant or anti-IL-5 Abs (not shown). Thus, despite our inability to measure extracellular GM-CSF, adequate concentrations were present to promote survival.



View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 5. Eosinophil survival is prolonged after GM-CSF mRNA transfection. PBEos were transfected, as described in Materials and Methods, with either naked beads (blank) or beads loaded with wild-type (AUUUA) or mutant GM-CSF (AUGUA) mRNAs. The viability was determined after 4 days by trypan blue exclusion. Neutralizing anti-GM-CSF mAb (a-GM) was added immediately after transfection. Each value represents the mean and SD of three cultures from the same donor representative of three different donors.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
In this study, we have shown for the first time that PBEos can be successfully transfected with both cDNA and mRNA. Based on unequivocal EGFP fluorescence in cells with characteristic eosinophil morphology, the transfection efficiency was 1.2%. This does not differ substantially from prior data in primary lymphocytes (26), but is less than we have observed with tumor cell lines (unpublished observations). As transfection requires cell membrane penetration by a 1-µm gold particle, efficiency is roughly proportional to cell diameter. Thus, lymphocytes and eosinophils are "hit" less frequently in PMGT than larger K562 cells or adherent fibroblasts. In an effort to increase transfection efficiency, we tried larger gold beads (up to 5 µm). However, efficiency decreased and cell death increased. One of the advantages of PMGT is that all transfected cells receive all nucleic acid loaded on that bead. Thus, cells can be transfected with beads loaded with several cDNAs/mRNAs. If one of the transgenes codes for a marker such as EGFP or cell surface protein, positive cells could be enriched by cell sorting or magnetic bead purification.

CMV-driven expression vectors were relatively inactive in PBEos. Transgenic promoter activity can only be compared in different cell types in relative terms because of differences in the efficiency of vector delivery. Based on signal quantification of pCMV-GM-CSF detection by PCR, PBEos and the eosinophil-like AM14.3D10 cell line exhibited similar transfection efficiencies. Therefore, observed differences in GM-CSF mRNA expression after pCMV-GM-CSF transfection most likely reflected differential promoter activity as opposed to transfection efficiency or GM-CSF mRNA decay. We do not know the underlying mechanism for promoter quenching in PBEos, but the data suggest that CMV-driven constructs will be poor choices for transgene expression. Although we have incompletely characterized the longevity of LTR activity, the high levels of EGFP expression suggest that this may be the superior promoter.

GM-CSF mRNA regulation in PBEos has not been investigated. In this study, we show that transfected GM-CSF mRNA decayed exceptionally rapidly, with a t1/2 of 8 min. Similar data have been observed in primary resting lymphocytes (28). Rapid GM-CSF mRNA decay required intact 3'-UTR AREs, as a mutant without these elements was 3-fold more stable. The AREs were also required for ionophore-mediated stabilization. These results are similar to those seen in activated lymphocytes (33) as well as fibroblasts (37). However, an accessory-stabilizing element in the proximal 3'-UTR upstream of the AREs has been proposed (33). This element was involved in mRNA stabilization by ionophore-mediated cell signaling, an effect not observed in this study. The rapid decay of mutant GM-CSF mRNA was somewhat unexpected. Irrespective of the precise identity of the additional destabilizer, the transfection of mutant GM-CSF mRNAs with additional deletions will permit its identification.

Several groups have recently characterized ARE-specific mRNA-binding proteins (17, 18, 19, 20). The overexpression of HuR was associated with the stabilization of ARE-containing mRNAs (21). We have recently identified a series of ARE-specific binding proteins in AML14.3D10 cells.4 These activities were significantly up-regulated after ionophore treatment, but none had molecular mass consistent with HuR. Thus, one mechanism for ionophore-mediated GM-CSF mRNA stabilization may be ARE masking by specific proteins. We are currently evaluating cytoplasmic lysates from PBEos for such activities.

Consistent with the very low levels of coding mRNA, transfected PBEos secreted undetectable levels of GM-CSF. AML14.3D10 cells secreted ~80 pg GM-CSF/ml/106 cells, at least 40-fold greater than produced by primary PBEos. As IL-4 and IL-10 are stored in cytoplasmic granules (35), it remained possible that transgenic GM-CSF was similarly sequestered. Indeed, ELISA of cytoplasmic protein after mRNA transfection revealed small, but detectable GM-CSF. However, even after mRNA transfection, PBEos translated considerably less GM-CSF protein than AML14.3D10 cells. As the decay rates were nearly identical, these data suggest that GM-CSF mRNA may also be under translational control in PBEos.

Despite levels below the sensitivity of the ELISA, secreted transgenic GM-CSF was produced and capable of blocking the apoptosis of PBEos in vitro. Survival required extracellular GM-CSF, as it was prevented by anti-GM-CSF-neutralizing Ab. We cannot exclude the remote possibility that GM-CSF secretion was necessary but not sufficient for PBEos survival. This would contradict a growing literature showing recombinant GM-CSF or IL-5 blocks eosinophil apotosis (36, 38, 39). We have confirmed these observations, although ~100–500 pg/ml of recombinant cytokine was necessary to achieve comparable survival, as shown in this study. Perhaps even more striking is that while only 1–2% of the cells were successfully transfected, 70% of the entire culture survived. Thus, small amounts of GM-CSF released in the immediate vicinity of nontransfected cells were sufficient to prevent apoptosis. It is possible that transgenic GM-CSF has greater biologic potency or t1/2 than recombinant protein produced by bacteria. We also suspect that continuous release may contribute to the effectiveness of transgenic GM-CSF, as the t1/2 of exogenous cytokine in culture is on the order of 2 h (not shown).

The successful transfection of normal PBEos using PMGT will enable a wide variety of possible studies, including the characterization of eosinophil-specific promoters as well as identification of mRNA instability determinants. In preliminary studies, we have introduced GM-CSF promoter constructs with luciferase reporters into PBEos (R. Horwitz and J. S. Malter, unpublished data). Despite the low transfection efficiency, adequate signals above background were observed. Thus, analysis of changes in gene expression and their underlying mechanisms as the eosinophil migrates from the periphery to the lung during asthma can now be evaluated.


   Acknowledgments
 
We greatly appreciate the creative and helpful comments from the laboratory and the remainder of the SCOR-asthma participants. We also thank the SCOR-Asthma Cell Core for providing eosinophils.


   Footnotes
 
1 This work was supported by the National Institutes of Health (Project 5 of Specialized Center of Research (SCOR) Asthma P50HL56396 to J.S.M.). Back

2 Address correspondence and reprint requests to Dr. James S. Malter, Department of Pathology and Laboratory Medicine A4/204-CSC, University of Wisconsin Hospital and Clinic, 600 Highland Avenue, Madison, WI 53792. E-mail address: Back

3 Abbreviations used in this paper: PBEos, peripheral blood eosinophils; ARE, adenosine-uridine-rich element; EGFP, enhanced green fluorescent protein; LTR, long terminal repeat; PMGT, particle-mediated gene transfer; UTR, untranslated region. Back

4 J. Ruth, S. Esnault, J. Jarzembowski, and J. Malter, Submitted for publication. Back

Received for publication May 18, 1999. Accepted for publication August 27, 1999.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Bousquet, J., P. Chanez, J. Y. Lacoste, G. Barneon, N. Ghavanian, I. Enander, P. Venge, S. Ahlstedt, J. Simony-Lafontaine, P. Godard. 1990. Eosinophilic inflammation in asthma. N. Engl. J. Med. 323:1033.[Abstract]
  2. Bochner, B., R. P. Schleimer. 1995. The role of adhesion molecules in human eosinophil and basophil recruitment. J. Allergy Clin. Immunol. 94:427.
  3. Wardlaw, A. J., G. M. Walsh, F. A. Symon. 1994. Mechanisms of eosinophil and basophil migration. Allergy 49:797.[Medline]
  4. Sedgwick, J. B., W. J. Calhoun, R. F. Vrtis, M. E. Bates, P. K. McAllister, W. W. Busse. 1992. Comparison of airway and blood eosinophil function after in vivo antigen challenge. J. Immunol. 149:3710.[Abstract]
  5. Yasruel, Z., M. Humbert, T. C. Kotsimbos, Y. Ploysongsang, E. Minshall, S. R. Durham, R. Pfister, G. Menz, J. Tavernier, A. B. Kay, Q. Hamid. 1997. Membrane-bound and soluble {alpha} IL-5 receptor mRNA in the bronchial mucosa of atopic and nonatopic asthmatics. Am. J. Respir. Crit. Care Med. 155:1413.[Abstract]
  6. Kroegel, C., J. C. Virchow, W. Luttmann, C. Walker, J. A. Warner. 1994. Pulmonary immune cells in health and disease. I. The eosinophil leukocyte. Eur. Respir. J. 7:519.[Abstract]
  7. Venge, J., M. Lampinen, L. Hakansson, S. Rak, P. Venge. 1996. Identification of IL-5 and RANTES as the major eosinophil chemoattractants in the asthmatic lung. J. Allergy Clin. Immunol. 97:1110.[Medline]
  8. Brown, J. R., J. Kleimberg, M. Marini, G. Sun, A. Bellini, S. Mattoli. 1998. Kinetics of eotaxin expression and its relationship to eosinophil accumulation and activation in bronchial biopsies and bronchoalveolar lavage (BAL) of asthmatic patients after allergen inhalation. Clin. Exp. Immunol. 114:137.[Medline]
  9. Owen, W. F., M. E. Rothenberg, D. S. Silberstein, J. C. Gasson, R. L. Stevens, K. F. Austen, R. J. Soberman. 1987. Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. J. Exp. Med. 166:129.[Abstract/Free Full Text]
  10. Sedgwick, J. B., S. F. Quan, W. J. Calhoun, W. W. Busse. 1995. Effect of interleukin-5 and granulocyte-macrophage colony stimulating factor on in vitro eosinophil function: comparison with airway eosinophils. J. Allergy Clin. Immunol. 96:375.[Medline]
  11. Broide, D. H., G. S. Firestein. 1991. Endobronchial allergen challenge in asthma: demonstration of cellular source of granulocyte macrophage colony-stimulating factor by in situ hybridization. J. Clin. Invest. 88:1048.
  12. Kita, H., T. Ohnishi, Y. Okubo, D. Weiler, J. S. Abrams, G. J. Gleich. 1991. Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. J. Exp. Med. 174:745.[Abstract/Free Full Text]
  13. Kim, J.-T., G. J. Gleich, H. Kita. 1997. Roles of CD9 molecules in survival and activation of human eosinophils. J. Immunol. 159:926.[Abstract]
  14. Bickel, M., R. B. Cohen, D. H. Pluznik. 1990. Post-transcriptional regulation of granulocyte-macrophage colony-stimulating factor synthesis in murine T cells. J. Immunol. 145:840.[Abstract]
  15. Lindsten, T., C. H. June, J. A. Ledbetter, G. Stella, C. B. Thompson. 1989. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 244:339.[Abstract/Free Full Text]
  16. Shaw, G., R. Kamen. 1986. A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46:659.[Medline]
  17. Malter, J. S.. 1989. Identification of an AUUUA-specific messenger RNA binding protein. Science 246:664.[Abstract/Free Full Text]
  18. Zhang, W., B. J. Wagner, K. Ehrenman, A. W. Schaefer, C. T. DeMaria, D. Crater, K. DeHaven, L. Long, G. Brewer. 1993. Purification, characterization, and cDNA cloning of an AU-rich element RNA-binding protein, AUF1. Mol. Cell. Biol. 13:7652.[Abstract/Free Full Text]
  19. Rajagopalan, L. E., J. S. Malter. 1994. Modulation of granulocyte-macrophage colony-stimulating factor mRNA stability in vitro by adenosine-uridine binding factor. J. Biol. Chem. 269:23882.[Abstract/Free Full Text]
  20. Nakamaki, T., J. Imamura, G. Brewer, N. Tsuruoka, H. P. Koeffler. 1995. Characterization of adenosine-uridine-rich RNA binding factors. J. Cell. Physiol. 165:484.[Medline]
  21. Fan, X. C., J. A. Steitz. 1998. Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J. 17:3448.[Medline]
  22. Esnault, S., J. A. Jarzembowski, J. S. Malter. 1998. Stabilization of granulocyte-macrophage colony-stimulating factor RNA in a human eosinophil-like cell line requires the AUUUA motifs. Proc. Assoc. Am. Physicians 110:575.[Medline]
  23. Kaufman, R. J.. 1997. DNA transfection to study translational control in mammalian cells. Methods 11:361.[Medline]
  24. Weaver, J. C., Y. A. Chizmadzhev. 1996. Theory of electroporation. Bioelectrochem. Bioenerg. 41:135.
  25. Deshmukh, H. M., L. Huang. 1997. Liposome and polylysine mediated gene transfer. N. J. Chem. 21:113.
  26. Burkholder, J. K., J. Decker, N.-S. Yang. 1993. Rapid transgene expression in lymphocyte and macrophage primary cultures after particle bombardment-mediated gene transfer. J. Immunol. Methods 165:149.[Medline]
  27. Rajagopalan, L. E., J. K. Burkholder, J. Turner, J. Culp, N.-S. Yang, J. S. Malter. 1995. Granulocyte-macrophage colony-stimulating factor mRNA stabilization enhances transgenic expression in normal cells and tissues. Blood 86:2551.[Abstract/Free Full Text]
  28. Rajagopalan, L. E., J. S. Malter. 1996. Turnover and translation of in vitro synthesized messenger RNAs in transfected, normal cells. J. Biol. Chem. 271:19871.[Abstract/Free Full Text]
  29. Hansel, T. T., I. J. M. de Vries, T. Iff, S. Rihs, M. Wandzilak, S. Betz, K. Blaser, C. Walker. 1991. An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J. Immunol. Methods 145:105.[Medline]
  30. Cheng, L., P. R. Ziegelhoffer, N.-S. Yang. 1993. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc. Natl. Acad. Sci. USA 90:4455.[Abstract/Free Full Text]
  31. Moqdel, R., Q. Hamid, S. Ying, J. Barkans, A. Hartnell, A. Tsicopoulos, A. J. Wardlaw, A. B. Kay. 1991. Expression of mRNA and immunoreactivity for the granulocyte/macrophage colony-stimulating factor in activated human eosinophils. J. Exp. Med. 174:749.[Abstract/Free Full Text]
  32. Wodnar-Filipowicz, A., C. Moroni. 1990. Regulation of interleukin 3 mRNA expression in mast cells occurs at the posttranscriptional level and is mediated by calcium ions. Proc. Natl. Acad. Sci. USA 87:777.[Abstract/Free Full Text]
  33. Iwai, Y., K. Akahane, D. H. Pluznik, R. B. Cohen. 1993. Ca2+ ionophore A23187-dependent stabilization of granulocyte-macrophage colony-stimulating factor messenger RNA in murine thymoma EL-4 cells is mediated through two distinct regions in the 3'-untranslated region. J. Immunol. 150:4386.[Abstract]
  34. Curatola, A. M., M. S. Nadal, R. J. Schneider. 1995. Rapid degradation of AU-rich element (ARE) mRNAs is activated by ribosome transit and blocked by secondary structure at any position 5' to the ARE. Mol. Cell. Biol. 15:6331.[Abstract]
  35. Nakajima, H., G. J. Gleich, H. Kita. 1996. Constitutive production of IL-4 and IL-10 and stimulated production of IL-8 by normal peripheral blood eosinophils. J. Immunol. 156:4859.[Abstract]
  36. Simon, H.-U., S. Yousefi, B. Dibbert, F. Levi-Schaffer, K. Blaser. 1997. Anti-apoptotic signals of granulocyte-macrophage colony-stimulating factor are transduced via Jak2 tyrosine kinase in eosinophils. Eur. J. Immunol. 27:3536.[Medline]
  37. Akashi, M., G. Shaw, M. Gross, M. Saito, H. P. Koeffler. 1991. Role of AUUU sequences in stabilization of granulocyte-macrophage colony-stimulating factor RNA in stimulated cells. Blood 78:2005.[Abstract/Free Full Text]
  38. Walsh, G. M., G. Dewson, A. J. Wardlaw, F. Levi-Schaffer, R. Moqbel. 1998. A comparative study of different methods for the assessment of apoptosis and necrosis in human eosinophils. J. Immunol. Methods 217:153.[Medline]
  39. Pazdrak, K., B. Olszewska-Pazdrak, S. Stafford, R. P. Garofalo, R. Alam. 1998. Lyn, Jak2, and Raf-1 kinases are critical for the antiapoptotic effect of interleukin 5, whereas only Raf-1 kinase is essential for eosinophil activation and degranulation. J. Exp. Med. 188:421.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Virol.Home page
K. Watashi, M. Khan, V. R. K. Yedavalli, M. L. Yeung, K. Strebel, and K.-T. Jeang
Human Immunodeficiency Virus Type 1 Replication and Regulation of APOBEC3G by Peptidyl Prolyl Isomerase Pin1
J. Virol., October 15, 2008; 82(20): 9928 - 9936.
[Abstract] [Full Text] [PDF]

Home page
 Int J EpidemiolHome page
F Salway, P. Day, W. Ollier, and T. Peakman
Levels of 5' RNA tags in plasma and buffy coat from EDTA blood increase with time
Int. J. Epidemiol., April 1, 2008; 37(suppl_1): i11 - i15.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
M. E. Bates, L. Y. Liu, S. Esnault, B. A. Stout, E. Fonkem, V. Kung, J. B. Sedgwick, E. A. B. Kelly, D. M. Bates, J. S. Malter, et al.
Expression of Interleukin-5- and Granulocyte Macrophage-Colony-Stimulating Factor-Responsive Genes in Blood and Airway Eosinophils
Am. J. Respir. Cell Mol. Biol., May 1, 2004; 30(5): 736 - 743.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Esnault and J. S. Malter
Hyaluronic Acid or TNF-{alpha} Plus Fibronectin Triggers Granulocyte Macrophage-Colony-Stimulating Factor mRNA Stabilization in Eosinophils Yet Engages Differential Intracellular Pathways and mRNA Binding Proteins
J. Immunol., December 15, 2003; 171(12): 6780 - 6787.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
L. Rainen, U. Oelmueller, S. Jurgensen, R. Wyrich, C. Ballas, J. Schram, C. Herdman, D. Bankaitis-Davis, N. Nicholls, D. Trollinger, et al.
Stabilization of mRNA Expression in Whole Blood Samples
Clin. Chem., November 1, 2002; 48(11): 1883 - 1890.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Esnault and J. S. Malter
Extracellular signal-regulated kinase mediates granulocyte-macrophage colony-stimulating factor messenger RNA stabilization in tumor necrosis factor-alpha plus fibronectin-activated peripheral blood eosinophils
Blood, May 13, 2002; 99(11): 4048 - 4052.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
R. Hoontrakoon, H. W. Chu, S. J. Gardai, S. E. Wenzel, P. McDonald, V. A. Fadok, P. M. Henson, and D. L. Bratton
Interleukin-15 Inhibits Spontaneous Apoptosis in Human Eosinophils via Autocrine Production of Granulocyte Macrophage-Colony Stimulating Factor and Nuclear Factor-kappa B Activation
Am. J. Respir. Cell Mol. Biol., April 1, 2002; 26(4): 404 - 412.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. E. Capowski, S. Esnault, S. Bhattacharya, and J. S. Malter
Y Box-Binding Factor Promotes Eosinophil Survival by Stabilizing Granulocyte-Macrophage Colony-Stimulating Factor mRNA
J. Immunol., November 15, 2001; 167(10): 5970 - 5976.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Esnault and J. S. Malter
Granulocyte Macrophage-Colony-Stimulating Factor mRNA Is Stabilized in Airway Eosinophils and Peripheral Blood Eosinophils Activated by TNF-{{alpha}} Plus Fibronectin
J. Immunol., April 1, 2001; 166(7): 4658 - 4663.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Esnault, S.
Right arrow Articles by Malter, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Esnault, S.
Right arrow Articles by Malter, J. S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS